Table 2.
Correlation of MYC and BCL2 expression and clinicopathological variables
| MYC, n (%) | BCL2, n (%) | ||||||
|---|---|---|---|---|---|---|---|
| Variablesa | <40 | ≥40 | P | <30 | ≥30 | P | |
| Age (yr) | mean ± SD | 57.6 ± 14.6 | 63.1 ± 7.6 | 0.097 | 50.4 ± 19 | 61.3 ± 10.4 | <0.001 |
| Age (yr) | ≤50 | 22 (95.7) | 1 (4.3) | 0.069 | 11 (47.8) | 12 (52.2) | 0.004 |
| >50 | 71 (78) | 20 (22) | 17 (18.7) | 74 (81.3) | |||
| Age (yr) | ≤60 | 46 (83.6) | 9 (16.4) | 0.584 | 18 (32.7) | 37 (67.3) | 0.051 |
| >60 | 47 (79.7) | 12 (20.3) | 10 (16.9) | 49 (83.1) | |||
| Sex | M | 55 (84.6) | 10 (15.4) | 0.335 | 20 (30.8) | 45 (69.2) | 0.076 |
| F | 38 (77.6) | 11 (22.4) | 8 (16.3) | 41 (83.7) | |||
| ECOG PS | 0, 1 | 62 (84.9) | 11 (15.1) | 0.172 | 19 (26) | 54 (74) | 0.731 |
| 2–4 | 29 (74.4) | 10 (25.6) | 9 (23.1) | 30 (76.9) | |||
| KPS | ≥70 | 81 (83.5) | 16 (16.5) | 0.136 | 24 (24.7) | 73 (75.3) | >0.999 |
| <70 | 9 (64.3) | 5 (35.7) | 3 (21.4) | 11 (78.6) | |||
| B symptoms | Absent | 88 (80.7) | 21 (19.3) | 0.582b | 26 (23.9) | 83 (76.1) | 0.595b |
| Present | 5 (100) | 0 (0) | 2 (40) | 3 (60) | |||
| Serum LDH | Normal | 54 (79.4) | 14 (20.6) | 0.506 | 19 (27.9) | 49 (72.1) | 0.582 |
| Elevated | 33 (84.6) | 6 (15.4) | 9 (23.1) | 30 (76.9) | |||
| Cell of origin | GCB | 22 (91.7) | 2 (8.3) | 0.236b | 11 (45.8) | 13 (54.2) | 0.005 |
| Non-GCB | 70 (78.7) | 19 (21.3) | 16 (18) | 73 (82) | |||
| Involvement of deep structure | Absent | 24 (80) | 6 (20) | 0.795 | 6 (20) | 24 (80) | 0.499 |
| Present | 69 (82.1) | 15 (17.9) | 22 (26.2) | 62 (73.8) | |||
| Extent of disease | Unifocal | 34 (81) | 8 (19) | 0.895 | 11 (26.2) | 31 (73.8) | 0.758 |
| Multifocal | 59 (81.9) | 13 (18.1) | 17 (23.6) | 55 (76.4) | |||
| Ocular involvement | Absent | 82 (81.2) | 19 (18.8) | >0.999b | 25 (24.8) | 76 (75.2) | >0.999b |
| Present | 10 (83.3) | 2 (16.7) | 3 (25) | 9 (75) | |||
| CSF protein | Normal | 31 (79.5) | 8 (20.5) | 0.844 | 8 (20.5) | 31 (79.5) | 0.157 |
| Elevated | 43 (81.1) | 10 (18.9) | 18 (34.0) | 35 (66.0) | |||
| CSF cytology | Negative | 66 (80.5) | 16 (19.5) | >0.999b | 19 (23.2) | 63 (76.8) | 0.121 |
| Positive | 11 (78.6) | 3 (21.4) | 6 (42.9) | 8 (57.1) | |||
| IELSG | 0–2 | 35 (81.4) | 8 (18.6) | 0.790 | 13 (30.2) | 30 (69.8) | 0.740 |
| 3–5 | 38 (79.2) | 10 (20.8) | 13 (27.1) | 35 (72.9) | |||
| Nottingham- Barcelona | 0–1 | 46 (86.8) | 7(13.2) | 0.154 | 16 (30.2) | 37 (69.8) | 0.229 |
| 2–3 | 45 (76.3) | 14 (23.7) | 12 (20.3) | 47(79.7) | |||
| MSKCC class | 1 | 21 (100) | 0 (0) | 0.012b | 10 (47.6) | 11 (52.4) | 0.008 |
| 2–3 | 70 (76.9) | 21 (23.1) | 18 (19.8) | 73 (80.2) | |||
Abbreviations: ECOG PS The Eastern Cooperative Oncology Group performance score, KPS Karnofsky performance status score, LDH lactate dehydrogenase, GCB germinal center B cell-like, CSF cerebrospinal fluid, IELSG the International Extranodal Lymphoma Study group, MSKCC Memorial Sloan Kettering Cancer Center
aSome cases have missing values that lacked the information about the variables
bFisher’s exact test